Smart Patients is an online community for patients and their families. Join us to talk with other patients about the latest research for your condition.
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
Overview
Status | Active not recruiting |
---|---|
Phase | Phase 2 |
Sponsor | University of Wisconsin, Madison |
Start date | June 2019 |
End date | December 2024 |
Enrollment | 48 participants |
Identifiers | NCT03972930, UW18149, 2019-0360, A533300, SMPH/HUMAN ONCOLOGY/HUMAN ONCO, NCI-2019-03768, Protocol Version 5/5/2021 |
Conditions
Treatments
Summary
One of the main challenges in treating sarcomas with radiation is the toxicity to normal structures around the sarcoma. Early reports suggest Hypofractionated Radiotherapy will be safe and effective for treatment of soft tissue sarcomas. However, given the rarity of this disease, the diversity of histological sub-types, and the variety of locations where these can occur (anywhere in the body), more data is needed to provide understanding of the safety and efficacy of hypofractionated radiotherapy for treatment of this disease. The hypothesis is that by using hypofractionated radiotherapy, highly conformal high dose radiation can be delivered to soft tissue sarcomas, while respecting established normal tissue constraints and that local control rates will be greater than historical rates reported with conventional fractionation.
Eligible participants with biopsy proven soft tissue sarcoma will be on study for up to 60 months.
Locations
University of Wisconsin | |
Madison, Wisconsin |